444 related articles for article (PubMed ID: 24390742)
1. Prostate cancer: the need for biomarkers and new therapeutic targets.
Felgueiras J; Silva JV; Fardilha M
J Zhejiang Univ Sci B; 2014 Jan; 15(1):16-42. PubMed ID: 24390742
[TBL] [Abstract][Full Text] [Related]
2. The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer.
Matos B; Howl J; Jerónimo C; Fardilha M
Pharmacol Res; 2020 Nov; 161():105145. PubMed ID: 32814172
[TBL] [Abstract][Full Text] [Related]
3. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.
Asim M; Massie CE; Orafidiya F; Pértega-Gomes N; Warren AY; Esmaeili M; Selth LA; Zecchini HI; Luko K; Qureshi A; Baridi A; Menon S; Madhu B; Escriu C; Lyons S; Vowler SL; Zecchini VR; Shaw G; Hessenkemper W; Russell R; Mohammed H; Stefanos N; Lynch AG; Grigorenko E; D'Santos C; Taylor C; Lamb A; Sriranjan R; Yang J; Stark R; Dehm SM; Rennie PS; Carroll JS; Griffiths JR; Tavaré S; Mills IG; McEwan IJ; Baniahmad A; Tilley WD; Neal DE
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26657335
[TBL] [Abstract][Full Text] [Related]
4. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer.
Abd Wahab NA; Lajis NH; Abas F; Othman I; Naidu R
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32131560
[TBL] [Abstract][Full Text] [Related]
6. Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets.
Fontana F; Raimondi M; Marzagalli M; Di Domizio A; Limonta P
Cells; 2020 Feb; 9(2):. PubMed ID: 32085497
[TBL] [Abstract][Full Text] [Related]
7. Targeting the relaxin hormonal pathway in prostate cancer.
Neschadim A; Summerlee AJ; Silvertown JD
Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063
[TBL] [Abstract][Full Text] [Related]
8. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
9. Insights into Chemoresistance of Prostate Cancer.
Zhang W; Meng Y; Liu N; Wen XF; Yang T
Int J Biol Sci; 2015; 11(10):1160-70. PubMed ID: 26327810
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Liao Y; Guo Z; Xia X; Liu Y; Huang C; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 Apr; 38(1):157. PubMed ID: 30975171
[TBL] [Abstract][Full Text] [Related]
11. Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy.
Leão R; Domingos C; Figueiredo A; Hamilton R; Tabori U; Castelo-Branco P
Urol Int; 2017; 99(2):125-136. PubMed ID: 28142149
[TBL] [Abstract][Full Text] [Related]
12. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.
Wen S; Niu Y; Lee SO; Chang C
Cancer Treat Rev; 2014 Feb; 40(1):31-40. PubMed ID: 23993415
[TBL] [Abstract][Full Text] [Related]
14. The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.
Chen Q; Zhong T
Drug Des Devel Ther; 2015; 9():5115-22. PubMed ID: 26379424
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
[No Abstract] [Full Text] [Related]
16. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
17. The role of genetic markers in the management of prostate cancer.
Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
[TBL] [Abstract][Full Text] [Related]
18. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways and targets in prostate cancer.
Shtivelman E; Beer TM; Evans CP
Oncotarget; 2014 Sep; 5(17):7217-59. PubMed ID: 25277175
[TBL] [Abstract][Full Text] [Related]
20. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
